NASDAQ: ABCLAbcellera Biologics Inc Stock
$2.03+0.02 (+1%)
Updated May 9, 2025
ABCL Price
$2.03
Fair Value Price
-$1.69
Market Cap
$605.92M
52 Week Low
$1.89
52 Week High
$4.34
P/E
-3.63x
P/B
0.59x
P/S
28.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.12M
Earnings
-$167.87M
Gross Margin
100%
Operating Margin
-911.24%
Profit Margin
-726.2%
Debt to Equity
0.31
Operating Cash Flow
-$78M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABCL Overview
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABCL's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ABCL
Ranked#422 of 458
Ranked#422 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $1.72 | A | |
| $44.23 | A | |
| $8.00 | A |
Be the first to know about important ABCL news, forecast changes, insider trades & much more!
ABCL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABCL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABCL ($2.03) is overvalued by 220.24% relative to our estimate of its Fair Value price of -$1.69 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABCL ($2.03) is not significantly undervalued (220.24%) relative to our estimate of its Fair Value price of -$1.69 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABCL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABCL due diligence checks available for Premium users.
Valuation
ABCL fair value
Fair Value of ABCL stock based on Discounted Cash Flow (DCF)
Price
$2.03
Fair Value
-$1.69
Undervalued by
220.24%
ABCL ($2.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABCL ($2.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABCL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABCL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.63x
Industry
-159.67x
Market
24.88x
ABCL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.59x
Industry
4.11x
ABCL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABCL's financial health
Profit margin
Revenue
$4.2M
Net Income
-$45.6M
Profit Margin
-1,077.2%
ABCL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABCL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$321.2M
Debt to equity
0.31
ABCL's short-term assets ($764.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABCL's short-term assets ($764.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABCL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.6M
Investing
$7.9M
Financing
$6.0M
ABCL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABCL vs Biotech Stocks
Abcellera Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.